Taysha Gene Therapies, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for TSHA, updated each market day.
TSHA AI Sentiment
AI predicts Taysha Gene Therapies, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Taysha Gene Therapies, Inc. Common Stock
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
Sector
Exchange
Market Cap
$1,330,059,567
Cap Tier
Employees
99
Headquarters
DALLAS, TX
Listed Since
Sept. 24, 2020
Website
TSHA Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
TSHA Volatility
Taysha Gene Therapies, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
